The pharmaceutical industry is entering a new era of validation and compliance. Upcoming updates to the EU GMP framework, according to the EMA 3-year work plan, together with the already revised (drafted) Chapter 4 - Documentation, Annex 11 Computerised Systems and Annex 22 Artificial Intelligence will reshaping how companies manage validation across systems, processes, data, and global operations.

At the same time, organizations face growing pressure to accelerate time-to-market, optimize resources, simplify validation activities, and maintain continuous inspection readiness in increasingly decentralized and digital environments.

This webinar explores the key challenges the industry will face over the coming years and how validation strategies must evolve to support operational agility, AI adoption, data integrity, and real-time compliance expectations from regulators such as the FDA and EU authorities.

Synopsis

Validation is no longer just a compliance exercise — it is becoming a strategic enabler for operational efficiency, digital transformation, and business continuity in the pharmaceutical industry.

In this webinar, we will analyze how evolving GMP expectations and the rapid adoption of digital technologies are changing the validation landscape. We will discuss the practical implications of new regulatory trends, including AI governance, continuous compliance, data integrity, remote validation models, and lifecycle-based validation approaches across global organizations.

Participants will gain insight into how leading pharmaceutical companies are adapting their validation frameworks to balance compliance, speed, scalability, and resource optimization in a highly regulated environment.

Key Learning Points

• Understand the expected impact on validation approach of upcoming EU GMP updates
• Explore how validation is evolving from periodic activities to a continuous lifecycle and risk-based approach.
• Identify the main challenges of implementing validation strategies across global and decentralized organizations.
• Learn how companies can reduce validation effort and accelerate product release timelines without compromising compliance.
• Understand the regulatory expectations
• Analyze the impact of Artificial Intelligence and automation on validation methodologies and GMP compliance.
• Discuss how organizations can prepare for increasing regulatory scrutiny, including unannounced FDA inspections and global inspection harmonization.
• Review emerging trends in digital validation, remote execution, and centralized compliance oversight models.